Navigation Links
Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures
Date:12/6/2008

data presented at AES are among the data supporting the New Drug Application (NDA) filed for carisbamate by J&JPRD in October 2008. If approved by the FDA, carisbamate will be marketed by Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Carisbamate has received provisional approval by the FDA to be marketed under the brand name of COMFYDE(TM).

About Partial Onset Seizures and Epilepsy

Epilepsy is one of the most common disorders of the nervous system, defined by recurrent unprovoked seizures. It is categorized as "primary generalized" or "partial onset" depending on the specific location of the abnormal electrical activity in the brain that characterizes the disorder. Partial-onset seizures are common and may often be difficult to treat. Partial-onset seizures are most often characterized by simple or complex repetitive movements, but virtually any sensory or emotional symptom can also occur as part of a partial seizure, including complex visual or auditory hallucinations. There are two categories of partial onset seizures: simple partial seizures (in which consciousness is retained), and complex partial seizures (in which consciousness is impaired or lost). Partial seizures can generalize and lead to tonic clonic seizures, during which the patient loses consciousness and is at risk for falling or injury.

About J&JPRD

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is a subsidiary of Johnson & Johnson, the world's most broadly-based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. More information can be found at

SOURCE Ortho-McNeil Neurologics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... -- Lee Tran & Liang LLP (LTL), ... and Yik Yak co-founder disputes, announced today ... most promising biotechnology start-ups in the country, Resilience Therapeutics, ... Sabados .  LTL represents Veronica Sara Weiner , ... fellow scientist at the Massachusetts Institute of Technology.      ...
(Date:6/1/2015)... 2015   Regulus Therapeutics Inc . ( ... discovery and development of innovative medicines targeting microRNAs, ... Ph.D. has resigned as President and Chief Executive ... of Directors, effective today, to pursue investment opportunities ... previously served as Chief Medical Officer of Regulus, ...
(Date:6/1/2015)... Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced data for ... a Phase 1 investigator-sponsored study at the University of ... at the 2015 American Society of Clinical Oncology (ASCO) ... Results from this study show a tolerable safety profile ... intravenously.  Based in part on the data ...
Breaking Medicine Technology:Lee Tran & Liang LLP Files Co-Founder Lawsuit against Leading Biotech Start-up Resilience 2Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 2Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 3Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 5
... DALLAS, Oct. 15 /PRNewswire-FirstCall/ -- ACCESS ... provided an update on its European commercial launch of ... debilitating side effect of radiation treatment and chemotherapy. ... five European countries, having been granted the CE mak ...
... Pharmaceuticals, Inc. announced today that new data confirm that ... of fat absorption in children aged 7-11 years who ... (CF). EPI is a condition resulting from a deficiency ... are necessary to digest nutrients in food. CREON® has ...
Cached Medicine Technology:Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback 4CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 2CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 3CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 4CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 5CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 6
(Date:6/1/2015)... 2015 On May 14, 2015, the ... hosted the Cherry Creek Chamber of Commerce for the ... care centers typically do not offer primary care services ... Cherry Creek Urgent Care staff to schedule family care ... 5:30 to 7:30 p.m. the center hosted presidents, CEOs, ...
(Date:6/1/2015)... Portland, Ore. (PRWEB) June 01, 2015 ... Plans (AHIP) announced today a new, interactive Affordable ... support large employers. The course, called “Affordable Care ... care professionals with the strategic and consultative insights ... employers as they navigate the impacts of the ...
(Date:6/1/2015)... June 01, 2015 Note: Dr. Julian ... in breast cancer prevention. , A phase III trial ... postmenopausal women with ductal carcinoma in situ (DCIS) now ... prevention. , The study (NSABP B-35/NRG Oncology) looked at ... the standard five-year treatment with tamoxifen to those who ...
(Date:6/1/2015)... June 01, 2015 More than 22 million ... months when school is out and they lose access to ... and America’s dairy farmers and milk companies are on a ... with The Great American Milk Drive. , In many ... in the school cafeteria for the bulk of their daily ...
(Date:6/1/2015)... 2015 June 1, 2015 – Atlanta, ... in the areas of hospital medicine, emergency medicine, and ... has expanded upon its partnership with AgileMD to provide ... Practice, in a mobile application format available on ... “We are very excited about the June 1 launch ...
Breaking Medicine News(10 mins):Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 2Health News:EB Medicine Expands Partnership With AgileMD To Launch Hospital Medicine Mobile Application 3
... fruit flies get high cholesterol and become obese? The same ... too rich in fats. More importantly, according to two ... fruit flies use the same molecular mechanisms as humans to ... of stored fat that contributes to obesity. The findings mean ...
... , ARLINGTON, Va., Dec. 2 ... life that give us meaning, joy and peace, the LIFE ... using the popular photo-sharing Web site flickr.com. The winning photos ... Foundation,s Web site at www.lifehappens.org/wondersphotos . , Contestants ...
... Dec. 2 Aegis Health Group, the nation,s leading ... chief development officer. As a member of Aegis, executive ... the sales and marketing staff as they focus on ... and physician relationships. , To this newly created position, ...
... point to death from TB, not Addison,s, researcher says ... Pride and Prejudice and Emma ... has long been believed, says one British scholar. , Since ... many historians and other experts have believed the cause was ...
... , LONDON, Dec. 2 ... therapies to treat lifestyle disorders. In the near future, the ... therapies and novel drugs to treat such conditions and reduce ... New analysis from Frost & Sullivan ( http://www.pharma.frost.com ), ...
... ... Links Medical Products Inc., an industry leader in healthcare products for hospitals ... Irvine Spectrum. The new facility is located at 9247 Research Drive, Irvine, ... Spectrum plus an assembly and distribution operation in Indio, California. This most ...
Cached Medicine News:Health News:Latest epidemic? High cholesterol, obesity in fruit flies 2Health News:Latest epidemic? High cholesterol, obesity in fruit flies 3Health News:Wonders of Life Photo Contest Winners Announced 2Health News:Wonders of Life Photo Contest Winners Announced 3Health News:Aegis Health Group Hires Pearson Talbert as Chief Development Officer 2Health News:New Light on Jane Austen's Final Chapter 2Health News:Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan 2Health News:Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan 3Health News:Links Medical Opens New Headquarters, Prepares to Launch Medical-Grade Manuka Honey 2Health News:Links Medical Opens New Headquarters, Prepares to Launch Medical-Grade Manuka Honey 3
Ruschelit® PVC. Magill tip-nasoral. Black positioning ring. High volume/low pressure cuff. X-ray opaque line. Graduated. Single use....
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. High volume/low pressure cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Gradua...
Laser resistant tubes for use with CO2 and KTP Lasers., ,Designed for airway management during laser surgery of the larynx or other areas in close proximity to the trachea....
Medicine Products: